XNAS · Healthcare · Drug Manufacturers - Specialty & Generic
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | Q1 2026 | -0.35 | -0.74 | -111.43% | $44.2M | ❌ Miss | -12.03% | -18.77% | — |
| 2026-03-02 | Q4 2025 | 0.45 | 0.17 | -62.22% | $89.1M | ❌ Miss | -13.75% | -34.41% | -33.89% |
| 2025-11-10 |
| Q3 2025 |
| 0.22 |
| 0.33 |
| +50.00% |
| $71.6M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-11 | Q2 2025 | 0.04 | 0.24 | +500.00% | $63.7M | ✅ Beat | +0.77% | +13.57% | +15.20% |
| 2025-03-27 | Q4 2024 | 0.13 | 0.40 | +207.69% | $66.8M | ✅ Beat | -5.96% | -13.67% | -11.55% |
| 2024-11-13 | Q3 2024 | -0.05 | -0.05 | +0.00% | $49.3M | ➖ Inline | -17.26% | -18.07% | -31.47% |
| 2024-08-07 | Q2 2024 | -0.07 | -0.06 | +14.29% | $48.9M | ✅ Beat | +54.32% | +68.56% | +72.79% |
| 2024-05-13 | Q1 2024 | -0.20 | -0.28 | -40.00% | $34.6M | ❌ Miss | +34.55% | +39.11% | +51.20% |
Showing last 8 quarters.